Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Vaccine crawled time : 00:00 save search
VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
Published: 2023-12-04 (Crawled : 00:00) - globenewswire.com
PCVX | $61.595 1.26% 1.24% 620K
|
Health Technology
|
| O: -0.15%
H: 1.65%
C: -0.72%
STRO | $3.77 3.86% 3.71% 520K
|
Health Technology
|
| O: -0.7%
H: 1.05%
C: -0.35%
vax-24 candidate pneumococcal vaccine lancet potential
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age
Published: 2023-08-21 (Crawled : 00:00) - biospace.com/
PFE | News A | $26.26 1.0% -0.08% 36M
|
Health Technology
|
| O: 0.14%
H: 1.3%
C: 0.82%
fda active vaccine respiratory virus
Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies
Published: 2023-04-16 (Crawled : 00:00) - globenewswire.com
PCVX | $61.595 1.26% 1.24% 620K
|
Health Technology
|
| O: 15.18%
H: 6.42%
C: 0.71%
STRO | $3.77 3.86% 3.71% 520K
|
Health Technology
|
| O: 0.68%
H: 8.13%
C: 5.64%
candidate conference pneumococcal vaccine results study phase 2
Tetanus toxoid vaccine market to grow at a CAGR of 4.3% from 2021 to 2026: Licensing agreements to drive market growth - Technavio
Published: 2023-04-05 (Crawled : 00:00) - prnewswire.com
CMXHF | $173.25 -19.21% 140
|
n/a
|
| O: 3.84%
H: 0.25%
C: -1.01%
CSLLY | $86.918 3.3% 60K
|
n/a
|
| O: 1.2%
H: 0.77%
C: 0.67%
GIKLY | $4.4 132.75% 150
|
Manufacturing
|
| O: -1.25%
H: 0.0%
C: 0.0%
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -0.21%
H: 3.44%
C: 3.44%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.36%
H: 2.91%
C: 2.91%
ZTS | $145.54 -0.66% 0.0% 4.3M
|
Health Technology
|
| O: 0.37%
H: 0.44%
C: 0.4%
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: 0.93%
H: 1.08%
C: 0.53%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 1.13%
H: 0.0%
C: 0.0%
vaccine growth market
Global Vaccine Contract Manufacturing Market Report 2023: Favorable Patient Demographics and Growing Vaccinations of Newborns and Children Fuels Sector
Published: 2023-03-09 (Crawled : 00:00) - prnewswire.com
LZAGF | $548.0 -19.1% 160
|
Health Technology
|
| O: -0.04%
H: 2.87%
C: 0.54%
LZAGY | $55.15 0.02% 49K
|
Professional, Scientific, and T...
|
| O: 0.72%
H: 1.11%
C: -0.37%
ICLR | News | $298.15 3.44% 3.33% 720K
|
Health Technology
|
| O: 0.83%
H: 0.0%
C: -4.27%
global report growing children vaccine contract favorable market
Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults
Published: 2023-02-28 (Crawled : 00:00) - biospace.com/
PFE | News A | $26.26 1.0% -0.08% 36M
|
Health Technology
|
| O: -0.69%
H: 0.52%
C: 0.17%
fda candidate vaccine rsv approval potential positive
PDS Biotech Announces Publication of Preclinical Infectimune™ Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses
Published: 2023-02-08 (Crawled : 00:00) - globenewswire.com
PDSB | $2.99 13.04% 11.54% 680K
|
Health Technology
|
| O: 2.43%
H: 2.61%
C: -2.73%
preclinical biotech vaccine publication infection
Aeolian Biotech Corp. Formed to Create an Improved Pneumococcal Vaccine with Experienced Vaccine Development Leadership Team
Published: 2023-01-30 (Crawled : 00:00) - biospace.com/
PFE | News A | $26.26 1.0% -0.08% 36M
|
Health Technology
|
| O: 0.0%
H: 0.79%
C: -0.55%
JNJ | News | $149.12 0.82% 0.0% 9.3M
|
Health Technology
|
| O: -0.18%
H: 0.36%
C: -3.53%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.95%
H: 0.0%
C: 0.0%
DVAX | $11.84 0.34% 0.34% 2.3M
|
Health Technology
|
| O: -0.84%
H: 0.0%
C: -2.81%
biotech vaccine pneumococcal
Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection
Published: 2022-11-16 (Crawled : 00:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: 0.0%
PFE | News A | $26.26 1.0% -0.08% 36M
|
Health Technology
|
| O: -0.52%
H: 1.45%
C: 1.11%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -2.28%
H: 0.0%
C: 0.0%
BNTX | News | $88.01 1.38% 1.36% 390K
|
Health Technology
|
| O: -1.45%
H: 2.36%
C: 2.31%
covid-19 candidate vaccine study
Clover’s Universal COVID-19 Booster Vaccine Candidate Demonstrates Superior Neutralization of Omicron BA.5 Compared to Inactivated Vaccine
Published: 2022-09-19 (Crawled : 00:00) - globenewswire.com
DVAX | $11.84 0.34% 0.34% 2.3M
|
Health Technology
|
| O: -1.69%
H: 3.4%
C: -0.77%
covid-19 candidate vaccine universal
Clover’s COVID-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine
Published: 2022-09-05 (Crawled : 00:00) - globenewswire.com
DVAX | $11.84 0.34% 0.34% 2.3M
|
Health Technology
|
| O: 1.61%
H: 0.0%
C: -5.62%
covid-19 candidate vaccine
Clover’s COVID-19 Booster Vaccine Candidate Demonstrates Robust Neutralization of Dominant Omicron BA.5
Published: 2022-08-29 (Crawled : 00:00) - globenewswire.com
DVAX | $11.84 0.34% 0.34% 2.3M
|
Health Technology
|
| O: 1.64%
H: 1.7%
C: 1.43%
covid-19 candidate vaccine
Sorrento Reports Promising Results With a Universal Chimeric mRNA COVID-19 Vaccine That Elicits Potent Neutralizing Antibodies and Protection Against Omicron (BA.1 and BA.2) and Delta Variants
Published: 2022-03-20 (Crawled : 00:00) - globenewswire.com
SRNE | $0.02 -8.85% 200K
|
Health Technology
|
| O: 3.44%
H: 1.48%
C: -7.38%
covid-19 covid report results vaccine antibody
Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial
Published: 2022-02-10 (Crawled : 00:00) - biospace.com/
NVAX | $4.09 3.02% 2.93% 2.3M
|
Health Technology
|
| O: -4.98%
H: 0.0%
C: 0.0%
covid-19 trial covid event-19 positive results positive vaccine phase 3
BERMUDA ANNOUNCES NEW COVID TRAVEL PROTOCOLS PROVIDING SAFE AND SIMPLE GUIDELINES FOR VACCINATED VISITORS
Published: 2022-02-07 (Crawled : 00:00) - prnewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: -5.78%
H: 0.0%
C: 0.0%
travel covid vaccine
Moderna to Host Conference Call on Phase 1 Interim Analysis for mRNA Flu Vaccine on Friday, December 10
Published: 2021-12-09 (Crawled : 00:00) - biospace.com/
MRNA | News S | $104.48 3.03% 2.94% 3.1M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
conference phase 1 vaccine phase 2
Innovent and NeoCura Announce Strategic Collaboration to Study the Combination Therapy of Sintilimab and Neoantigen Vaccine NEO_PLIN2101 for Cancer Treatment in China
Published: 2021-10-28 (Crawled : 00:00) - prnewswire.com
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: -0.0%
H: 2.63%
C: 1.28%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: 0.49%
H: 1.01%
C: 0.69%
treatment china therapy collaboration cancer vaccine
U.S. CDC Advisory Committee Unanimously Recommends Johnson & Johnson COVID-19 Vaccine as a Booster for All Eligible Individuals Who Receive Authorized COVID-19 Vaccines
Published: 2021-10-21 (Crawled : 00:00) - prnewswire.com
JNJ | News | $149.12 0.82% 0.0% 9.3M
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: 0.0%
covid authorized vaccine covid-19
Vaxart To Present at Upcoming Vaccine Conferences
Published: 2021-09-22 (Crawled : 00:00) - biospace.com/
VXRT | News | $0.7625 0.91% 0.9% 940K
|
Health Technology
|
| O: 0.87%
H: 1.96%
C: 0.49%
vaccine conference presentation
Global Regulators Envision Paradigm Shift Toward Inclusion of Pregnant and Breastfeeding Women in Clinical Research for Medicines and Vaccines
Published: 2021-07-19 (Crawled : 00:00) - fda.gov
JNJ | News | $149.12 0.82% 0.0% 9.3M
|
Health Technology
|
| O: 0.01%
H: 2.34%
C: 0.93%
vaccine
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.